OPTHEA LIMITED has not announced any capital raises, but we are collecting interest for future raises.
1. Create Account
Complete your onboarding digitally in less than 3 minutes.
2. View Terms
View the full term sheet for the capital raise.
3. Bid for Allocation
Submit and track your bid online.
Opthea Limited (OPT, formerly Circadian Technologies Limited) is a biologics drug developer focusing on ophthalmic disease therapies. Opthea's lead molecule is OPT-302 for the treatment of �back of the eye' disease such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT-302 is a soluble form of VEGFR-3 that acts a VEGF-C/VEGF-D 'trap'. Former Names Circadian Technologies Limited (CIR), 11/12/2015
Unit 4/650 Chapel St, South Yarra VIC 3141, Australia
Fresh Equities does not have OPTHEA LIMITED news data.